| Species |
Human |
| Protein Construction |
CD89 (Gln22-Asn227)
Accession # NP_001991.1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
24.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 45-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD89 (Fc alphaRI) is the human myeloid IgA Fc receptor expressed on cells, such as neutrophils, eosinophils and monocytes/macrophages.CD89 is a transmembrane glycoprotein that binds both subclasses of IgA in all its molecular forms (i.e. monomeric, dimeric and secretory IgA) via a region of its membrane-distal EC1 domain. |
| Synonyms |
IgA Fc receptor; CD89; FCAR; CTB-61M7.2; FcalphaRI; Fc fragment of IgA |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
